In 1999, the first clinical trials started using an anti-CD40L antibody as a treatment for systemic lupus erythematosus, lupus glomerulonephritis, and immune thrombocytopenic purpura. This evidence concerns the gene CD40LG and autoimmune thrombocytopenic purpura.